UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

The New England journal of medicine, 2023-02, Vol.388 (8), p.694-705

2023

Volltextzugriff (PDF)

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Drugs in R&D, 2024-09, Vol.24 (3), p.359-381

2024

Volltextzugriff (PDF)

A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report

Clinical case reports, 2023-01, Vol.11 (1), p.e6831-n/a

2023

Volltextzugriff (PDF)

Anti–Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support

JACC. Heart failure, 2015-04, Vol.3 (4), p.314-322

2015

Volltextzugriff (PDF)

Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective

Critical reviews in oncology/hematology, 2022-06, Vol.174, p.103678-103678, Article 103678

2022

Volltextzugriff (PDF)

Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients

Thrombosis and haemostasis, 2002-10, Vol.88 (4), p.568-575

2002

Volltextzugriff (PDF)

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-07, Vol.26 (4), p.e201-e204

2020

Volltextzugriff (PDF)

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature

Haemophilia : the official journal of the World Federation of Hemophilia, 2023-01, Vol.29 (1), p.33-44

2023

Volltextzugriff (PDF)

The impact of obesity on chronic pain in patients with haemophilia: A multicentre retrospective analysis

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-03, Vol.30 (2), p.567-570

2024

Volltextzugriff (PDF)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

Thrombosis and haemostasis, 2021-08, Vol.121 (8), p.1079-1086

2021

Volltextzugriff (PDF)

Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia

European journal of haematology, 2012-10, Vol.89 (4), p.361-364

2012

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII

Acta haematologica, 2024-04, p.1-10

2024

Volltextzugriff (PDF)

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

Thrombosis research, 2019-11, Vol.183, p.13-19

2019

Volltextzugriff (PDF)

Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A

European journal of haematology, 2024-02, Vol.112 (2), p.286-295

2024

Volltextzugriff (PDF)

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-05, Vol.27 (3), p.e347-e356

2021

Volltextzugriff (PDF)

Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients

Haematologica (Roma), 2007-08, Vol.92 (8), p.1029-1036

2007

Volltextzugriff (PDF)

Hemophilic Arthropathy of the Elbow

Hand clinics, 2011-05, Vol.27 (2), p.151-163

2011

Volltextzugriff (PDF)

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A

Journal of thrombosis and haemostasis, 2024-07, Vol.22 (7), p.1880-1893

2024

Volltextzugriff (PDF)

Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients

The Journal of heart and lung transplantation, 2018-08, Vol.37 (8), p.1038-1040

2018

Volltextzugriff (PDF)

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.e559-e562

2021

Volltextzugriff (PDF)

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-11, Vol.25 (6), p.1011-1019

2019

Volltextzugriff (PDF)

Opioid exposure in haemophilia patients is common and underreported

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-03, Vol.26 (2), p.251-256

2020

Volltextzugriff (PDF)

Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia

Blood cells, molecules, & diseases, 2019-07, Vol.77, p.109-112

2019

Volltextzugriff (PDF)

Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects

Thrombosis and haemostasis, 2000-10, Vol.84 (4), p.643-652

2000

Volltextzugriff (PDF)

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-11, Vol.27 (6), p.911-920

2021

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(134)

Publikationsform

Sprache

Englisch
(147)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report

Anti–Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support

Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective

Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature

The impact of obesity on chronic pain in patients with haemophilia: A multicentre retrospective analysis

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia

Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients

Hemophilic Arthropathy of the Elbow

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A

Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

Opioid exposure in haemophilia patients is common and underreported

Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia

Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors

Suchergebnisse filtern